1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications
    Meeting Abstract

    D'Angelo, S. P.; Antonescu, C. R.; Keohan, M. L.; Carvajal, R. D.; Dickson, M. A.; Gounder, M. M.; Moraco, N. H.; Singer, S.; Schwartz, G. K.; Tap, W. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma
    Meeting Abstract

    Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; Testori, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Cella, D.; Davis, M. P.; Bushmakin, A. G.; Cappelleri, J. C.; Hahn, E. A.; Korytowsky, B.; Bhattacharyya, H.; Sandin, R.; Beaumont, J. L.; Matczak, E.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer
    Meeting Abstract

    Cercek, A.; Siegel, C.; Reidy, D. L.; Saltz, L.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized phase III, multicenter, open-label study comparing TH-302 in combination with doxorubicin versus doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma
    Meeting Abstract

    Chawla, S. P.; Reinke, D. K.; Saks, S.; Kroll, S.; Tap, W. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Quantitating pathologic response to neoadjuvant chemotherapy in KRAS-mutated versus nonmutated lung cancers
    Meeting Abstract

    Chaft, J. E.; Paik, P. K.; Sima, C. S.; Kris, M. G.; Krug, L. M.; Azzoli, C. G.; Riely, G. J.; Pietanza, M. C.; Rusch, V. W.; Travis, W. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy
    Meeting Abstract

    Carvajal, R. D.; Chugh, R.; Milhem, M. M.; Ryan, C. W.; George, S.; Chmielowski, B.; Agulnik, M.; Rodler, E. T.; Elias, A. D.; Budd, G. T.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma
    Meeting Abstract

    Carvajal, R. D.; Ambrosini, G.; Wolchok, J. D.; Chapman, P. B.; Dickson, M. A.; D'Angelo, S. P.; Bluth, M. J.; Paucar, D.; Fusco, A.; Bohr, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Competing causes of mortality in long-term survivors of head and neck cancer
    Meeting Abstract

    Baxi, S. S.; Pinheiro, L. C.; Patil, S.; Pfister, D. G.; Oeffinger, K. C.; Elkin, E. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial
    Meeting Abstract

    Baurain, J. F.; Smylie, M.; Ascierto, P. A.; Roman, L.; Houston, S.; Konto, C.; Chin, K. M.; Chen, T. T.; Francis, S.; Wolchok, J. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save